This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provision ResourcesMaterials
What were the key features of the PALOMA-3 trial?

PALOMA-3 was a randomised, double-blind, placebo-controlled, Phase III study to assess the efficacy of IBRANCE in combination with fulvestrant in pre-/peri- and post-menopausal women with HR+/HER2- mBC who had progressed on or after prior ET1

PALOMA-3 Trial Design1Adapted from Cristofanilli M, et al. 2016.¹
Defined as progression during or within 1 month after the end of prior ET in the context of metastatic disease or progression during or within 12 months after discontinuation of adjuvant ET. 21% of patients had not received prior treatment for their metastatic disease (1st line). Pre-/peri-menopausal patients received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of the trial.¹ Sensitivity to prior hormonal therapy was defined as documented clinical benefit (CR, PR, or SD ≥24 weeks) to ≥1 prior hormonal therapy regimen in the metastatic setting or ≥24 months of adjuvant hormonal therapy before recurrence.¹
Evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.1 ORR was defined as confirmed CR or PR.1CBR was defined as CR or PR or SD for ≥24 weeks.1​​​​​​​
Adapted from Cristofanilli M, et al. 2016.¹Pre-/peri-menopausal patients received goserelin or an alternative LHRH agonist for at least 4 weeks prior to and for the duration of the trial.1,2Explore More PALOMA-2

See trial design 

Learn more

See trial design 

Learn more
Expert opinion

Find out what experts are saying about the PALOMA-2 clinicaI triaI design
​​​​​​​Expert opinion (Placeholder for local video content)

Learn more
AI = aromatase inhibitor; CDK = cyclin-dependent kinase; CNS = central nervous system; CR = complete response; CT = chemotherapy; ECOG = Eastern Cooperative Oncology Group; ET = endocrine therapy; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; IM = intramuscularly; LHRH = luteinising hormone-releasing hormone; mBC = metastatic breast cancer; mTOR = mechanistic target of rapamycin; N/n = number of patients; PI3K = phosphoinositide 3-kinase; PFS= progression-free survival; PR = partial response; RECIST = Response Evaluation Criteria In Solid Tumors; SD = stable disease.References:Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
IBRANCE EPAR Public assessment report. 25 November 2016. Available at:
assessment-report/ibrance-epar-public-assessment-report_en.pdf. Last accessed January 2023.
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0695 January 2024

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0784. June 2024